VectorY Therapeutics is a gene therapy company that was founded in 2020. Forbion Operating Partner and gene‑therapy pioneer Sander van Deventer is credited with conceiving the company’s scientific concept of developing the idea to build a fully integrated gene‑therapy company using vectorized antibodies. VectorY’s platform uniquely combines vectorized antibodies with a premier gene therapy technology to target some of the most challenging disorders of the central nervous system.

Focus on high‑impact rare diseases

VectorY develops first in class programs for the following conditions with profound unmet need:

• Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare neurodegenerative disease characterized by the rapid and progressive loss of motor neurons, leading to paralysis, and death due to the inability to breathe. It is a fatal disease, with most individuals dying from complications such as respiratory failure within 3 to 5 years of diagnosis, though some may survive longer. VectorY’s lead drug candidate, VTx 002, has the potential to significantly delay disease progression and preserve quality of life in the majority of people with ALS.
• Huntington’s disease (HD) is an inherited condition that causes the brain to gradually stop working properly over time. Although a person is born with the gene that causes Huntington’s, its symptoms usually do not appear until adulthood, often between the ages of 30 and 50. The disease affects how people move, think, and feel. There is currently no cure, and it can lead to serious health problems and, eventually, be life-threatening. VectorY’s platform targets misfolded proteins and intracellular dysfunction, offering a novel mechanism in a disease without curative options.
• Other rare CNS conditions: The platform extends to additional protein misfolding disorders, including subsets of Parkinson’s disease.

This approach allows metal extraction to be combined with progressive land restoration, rather than long‑term ecological damage. Phytomining reframes metal extraction as a regenerative land‑use activity, aligned with biodiversity protection and responsible land stewardship.

A platform designed to overcome CNS therapeutic barriers

VectorY’s technology directly addresses the challenges that have long limited progress in neurodegeneration, such as poor CNS penetration, intracellular targets, and limited treatment durability. For rare disease patients, particularly those with ALS, where life expectancy after diagnosis is typically 3–5 years, VectorY’s approach has the potential to meaningfully extend functional ability, slow decline, and improve quality of life. The company has taken important steps toward bringing a new therapy to people living with ALS. In late 2025, U.S. regulators gave the green light to begin clinical testing of VTx‑002, marking the transition from years of research to studies in patients.